ClinicalTrials.gg
RecruitingNCT06010238SAVEFGRUpdated Nov 4, 2026

STV Analysis Versus Visual Evaluation of Cardiotocography in FGR

An interventional study of Short term variation and Visual interpretation in Fetal Growth Retardation, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 6 sites in Netherlands. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 4, 2026Now RecruitingFirst site in Netherlands+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Fetal Growth Retardation with a site in Netherlands — 7 open to participants now, 7 under way, none of them phase 3. Fetal Growth Retardation · Netherlands.

Started
2025
with 1 other
No phase
3 of 11
2 open now
Registered
9th of 11
by date
Lead sponsor
2 of 11
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 11 studies in Fetal Growth Retardation with a site in Netherlands, this one is one of 2 that started in 2025, is one of 3 with no phase, and was the 9th registered.

Fetal Growth Retardation

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

Browse Fetal Growth Retardation studies →

Open to participants now

7 of the 11 studies in Fetal Growth Retardation with a site in Netherlands are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 99 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Fetal Growth Retardation with a site in Netherlands, or all of them as a file.
02

Study summary

This stepped wedge cluster randomized clinical trial investigates whether in pregnant women with severe, early-onset fetal growth restriction, the use of STV analysis in fetal monitoring improves the chances of perinatal survival, compared with visual evaluation of the cardiotocography.

Read the detailed description

Severe, early-onset fetal growth restriction (FGR, \<32 weeks gestation) is a condition in which the fetus does not reach its growth potential due to placental insufficiency[. This condition affects about 0.3% of pregnancies, accounting for an estimated 15,000 babies in Europe being born premature below 32 weeks gestation. The main clinical dilemma of FGR lies in the timing of birth, given the balance of risks of antenatal mortality and severe damage to organs and the aggravated neonatal effects of prematurity: death or survival with severe neurodevelopmental impairment. The mainstay of clinical management in these cases pivots around the anticipation of the risk of fetal demise from placental oxygenation failure. The monitoring variables that are currently available comprise assessment of the severity of metabolic insufficiency (fetal size and growth, Doppler ultrasound, serum biomarkers) and the early detection of progressive fetal hypoxia with cardiotocography (CTG). The common approach is to deliver the fetus when signs of advanced hypoxia appear on CTG. A delicate balance exists between having the fetus born (too) early and facing the risks of extreme prematurity combined with a very low birthweight; and between delivering the fetus (too) late when the fetus has the disadvantage of hypoxia at birth. The decision when to deliver the fetus, is made mostly based on the CTG. The inter- and intra-observer variability could be overcome by software analysis according to the original Dawes\&Redman algorithm. The software calculates the short-term variation (STV) of the inter-beat interval expressed in milliseconds, and a range of secondary calculations. In contrast with repeated decelerations, when fetal hypoxia is considered evident, the place of the software analysis of the fetal heart rate variability is less clear. Although the advantages of mathematized and uniform quantification of the fetal heart rate variability appear self-evident, there are no studies with sufficient power to detect an association of intervention based on STV at any threshold with the most important outcomes: fetal death and long-term infant outcome.

The purpose of this study is to assess the outcomes of monitoring the fetal condition with STV in computerized CTG compared to visual interpretation of the CTG in order to time delivery in pregnant women with severe, early-onset FGR.

03

Conditions studied

  • Fetal Growth Retardation

Keywords

  • fetal growth restriction
  • cardiotocography
  • perinatal death
  • short term variation
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women with a singleton pregnancy between 24 weeks and 0 days and 31 weeks and 6 days with severe, early-onset fetal growth restriction, admitted in hospital or frequently evaluated ambulatory by CTG (according to local protocol) for fetal monitoring.
  • Fetal growth restriction is defined in line with the international Delphi consensus as biometric ultrasound measurement of the abdominal circumference (AC) OR a combination of measurements resulting in an estimated fetal weight (EFW) below the 3rd percentile (\<p3) OR a combination of EFW \<p10 AND uterine artery pulsatility index (PI) >p95 OR umbilical artery Doppler PI >p95.
  • Maternal age ≥ 18 years.
  • Able to provide written for collection and use of data on informed consent form in available language.

Exclusion criteria

Exclusion Criteria:

  • Known congenital or chromosomal anomalies influencing perinatal outcome.
  • Imminent labour or expected maternal indication for delivery \< 48 hours.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Active comparator
    Visual interpretation of cardiotocography

    Monitoring by visual interpretation of cardiotocography

    Device: Visual interpretation

  • Experimental
    Short term variation

    Short term variation by computer software analysis

    Device: Short term variation

Interventions

  • DeviceShort term variation

    Short term variation in computer software analysis

  • DeviceVisual interpretation

    Visual interpretation of cardiotocography

06

What researchers measure

Primary outcomes

  1. Proportion of pregnancies resulting in perinatal death

    Perinatal death is defined as antenatal death or neonatal/infant death before discharge from NICU

    Time frame: Before discharge from neonatal intensive care unit (NICU), up to 1 year

Secondary outcomes

  1. Proportion of children with major neonatal morbidity

    Major neonatal morbidity is a composite outcome defined as intraventricular hemorrhage grade 3 or more, periventricular leukomalacia grade 2 or more, moderate or severe bronchopulmonary dysplasia, necrotizing enterocolitis Bell stage 2 or more, or retinopathy of prematurity requiring therapy.

    Time frame: Before discharge from NICU, up to 1 year

  2. Proportion of children with neonatal morbidities

    Individual neonatal morbidities of the abovementioned composite outcome and additionally persisting ductus arteriosus, persistent pulmonary hypertension of the newborn (PPHN), respiratory distress syndrome (RDS), period of invasive mechanical ventilation in days, medication need, hypoglycaemia, neonatal jaundice, sepsis and cardiovascular function.

    Time frame: Before discharge from NICU, up to 1 year

  3. Proportion of children with neurodevelopmental impairment

    Neurodevelopmental impairment is defined as an abnormal test on Bayley III Dutch version (or version IV if available) (composite cognitive score \< 85, composite motor score \< 85), cerebral palsy, with a Gross Motor Function Classification System (GMFCS) grade \> 1, hearing loss needing hearing aids, or severe visual loss (legally certifiable as blind or partially sighted) assessed at two years of corrected age

    Time frame: At two years of corrected age

07

Study locations

1 of 6 sites recruiting
08

References and documents

Publications

  • Bruins ME, Prins LI, Pels A, Groen H, Lokkegaard ECL, Jacquemyn Y, Scholz A, Onland W, Leemhuis AG, Papageorghiou AT, Figueras F, Gordijn SJ, Ganzevoort W. The SAVE FGR study: Short term variation Analysis versus Visual Evaluation of cardiotocography in early-onset Fetal Growth Restriction to trigger expedited birth - study protocol for a stepped wedge cluster randomized trial. BMC Pregnancy Childbirth. 2026 Feb 21;26(1):343. doi: 10.1186/s12884-026-08695-0. PubMed 41723364 ↗

Individual participant data

Plan to share: No — There is no current plan, but data will be available upon collaboration request

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

Of 39 non-industry interventional studies with no phase under Fetal Growth Retardation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 52. This study's planned 18 months is below that.

Counting every sponsor, half of 40 studies reached it within 35 months; a quarter within 18 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Jan 2025 → Jun 2025, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 24, 2023
StartActual
Jun 18, 2025was Jan 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
6 sites added — first site in Netherlands
Show 6 added (6 Netherlands)
  • University Medical Center Groningen · Groningen, Netherlands
  • Amsterdam University Medical Center · Amsterdam, Netherlands
  • Maastricht University Medical Center+ · Maastricht, Netherlands
  • Radboud University Medical Center · Nijmegen, Netherlands
  • Erasmus MC University Medical Center · Rotterdam, Netherlands
  • Isala · Zwolle, Netherlands
Nov 4, 2026
Start date
Jan 1, 2025→Jun 18, 2025 (actual)
Nov 4, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41723364 ↗
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41723364 ↗
    6 sites added — first site in Netherlands
    Show 6 added (6 Netherlands)
    • University Medical Center Groningen · Groningen, Netherlands
    • Amsterdam University Medical Center · Amsterdam, Netherlands
    • Maastricht University Medical Center+ · Maastricht, Netherlands
    • Radboud University Medical Center · Nijmegen, Netherlands
    • Erasmus MC University Medical Center · Rotterdam, Netherlands
    • Isala · Zwolle, Netherlands
    Start date Jan 1, 2025→Jun 18, 2025 (now actual)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06010238
Responsible party
Wessel Ganzevoort (Principal investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Aug 24, 2023
Start date
Jun 18, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Wessel Ganzevoort, MD PhD
Contact
j.w.ganzevoort@amsterdamumc.nl
003120-5669111
Anouk Pels, MD PhD
Contact
a.pels@amsterdamumc.nl
003120-5669111
Wessel Ganzevoort, MD PhD
principal investigator · Amsterdam UMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion